Skip to main content

Publications

What type of publication do you want to show?

2023

A randomized clinical trial of on-demand oral pre-exposure prophylaxis does not modulate lymphoid/myeloid HIV target cell density in the foreskin

Rametse, C. L., Webb, E., Herrera, C., Alinde, B., Besethi, A., Motaung, B., . . . CHAPS, C. (2023). A randomized clinical trial of on-demand oral pre-exposure prophylaxis does not modulate lymphoid/myeloid HIV target cell density in the foreskin. AIDS, 37(11), 1651-1659. doi:10.1097/QAD.0000000000003619

DOI
10.1097/QAD.0000000000003619
Journal article

Application of novel plasma separation filter cards for quantification of nucleoside/nucleotide reverse transcriptase inhibitor di/triphosphates in dried blood spot using LC-MS

Thompson, B., Dilly-Penchala, S., Amara, A., Reynolds, H., Khoo, S., & Else, L. (2023). Application of novel plasma separation filter cards for quantification of nucleoside/nucleotide reverse transcriptase inhibitor di/triphosphates in dried blood spot using LC-MS. BIOANALYSIS, 15(13), 739-756. doi:10.4155/bio-2023-0057

DOI
10.4155/bio-2023-0057
Journal article

2019

2016

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . Puls, R. (2016). Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study. CLINICAL PHARMACOKINETICS, 55(7), 861-873. doi:10.1007/s40262-015-0360-5

DOI
10.1007/s40262-015-0360-5
Journal article

2015

Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation

Dickinson, L., Yapa, H. M., Jackson, A., Moyle, G., Else, L., Amara, A., . . . Boffito, M. (2015). Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(10), 6080-6086. doi:10.1128/AAC.01441-15

DOI
10.1128/AAC.01441-15
Journal article

Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.

Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . Puls, R. (2015). Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.. Clinical pharmacology and therapeutics, 98(4), 406-416. doi:10.1002/cpt.156

DOI
10.1002/cpt.156
Journal article

Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study

Olagunju, A., Bolaji, O., Amara, A., Waitt, C., Else, L., Adejuyigbe, E., . . . Owen, A. (2015). Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study. Clin Infect Dis, 61(3), 453-463. doi:10.1093/cid/civ317

DOI
10.1093/cid/civ317
Journal article

Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies

Waitt, C. J., Garner, P., Bonnett, L. J., Khoo, S. H., & Else, L. J. (2015). Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(7), 1928-1941. doi:10.1093/jac/dkv080

DOI
10.1093/jac/dkv080
Journal article

Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study

Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . R Puls, O. B. O. T. E. S. G. (2015). Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study. Clin Pharmacol Ther, 98(4), 406-416.

Journal article

A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers

Mora-Peris, B., Else, L., Goldmeier, D., Mears, A., Weston, R., Cooke, G., . . . Winston, A. (2015). A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(6), 1812-1815. doi:10.1093/jac/dkv035

DOI
10.1093/jac/dkv035
Journal article

Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression.

Di Yacovo, M. S., Moltó, J., Ferrer, E., Curran, A., Else, L., Gisslén, M., . . . Podzamczer, D. (2015). Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression.. The Journal of antimicrobial chemotherapy, 70(5), 1513-1516. doi:10.1093/jac/dku558

DOI
10.1093/jac/dku558
Journal article

Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically-defined subgroups of mother-infant pairs: an observational study.

Olagunju, A., Bolaji, O., Amara, A., Waitt, C., Else, L., Adejuyigbe, E., . . . Owen, A. (2015). Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically-defined subgroups of mother-infant pairs: an observational study.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Journal article

Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics

Olagunju, A., Bolaji, O., Amara, A., Else, L., Okafor, O., Adejuyigbe, E., . . . Owen, A. (2015). Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics. CLINICAL PHARMACOLOGY & THERAPEUTICS, 97(3), 298-306. doi:10.1002/cpt.43

DOI
10.1002/cpt.43
Journal article

Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics.

Olagunju, A., Bolaji, O., Amara, A., Else, L., Okafor, O., Adejuyigbe, E., . . . Owen, A. (2015). Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics.. Clinical pharmacology and therapeutics, 97(3), 298-306.

Journal article

A PHASE 1 STUDY TO ASSESS THE SAFETY, TOLERABILITY AND PHARMACOKINETIC PROFILE OF BOCEPREVIR AND SILDENAFIL WHEN DOSED SEPARATELY AND TOGETHER, IN HEALTHY MALE VOLUNTEERS

Mora-Peris, B., Else, L., Goldmeier, D., Mears, A., Weston, R., Graham, C., . . . Winston, A. (2015). A PHASE 1 STUDY TO ASSESS THE SAFETY, TOLERABILITY AND PHARMACOKINETIC PROFILE OF BOCEPREVIR AND SILDENAFIL WHEN DOSED SEPARATELY AND TOGETHER, IN HEALTHY MALE VOLUNTEERS. SEXUALLY TRANSMITTED INFECTIONS, 91, A78. doi:10.1136/sextrans-2015-052126.231

DOI
10.1136/sextrans-2015-052126.231
Journal article

Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS

Olagunju, A., Bolaji, O. O., Amara, A., Waitt, C., Else, L., Soyinka, J., . . . Khoo, S. (2015). Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(2), 555-561. doi:10.1093/jac/dku420

DOI
10.1093/jac/dku420
Journal article

Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS.

Olagunju, A., Bolaji, O. O., Amara, A., Waitt, C., Else, L., Soyinka, J., . . . Khoo, S. (2015). Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS.. The Journal of antimicrobial chemotherapy, 70(2), 555-561.

Journal article

The pharmacokinetic profile of raltegravircontaining antiretroviral therapy in HIV-infected individuals over 60 years of age

Vera, J. H., Jackson, A., Dickinson, L., Else, L., Barber, T., Mora-Peris, B., . . . Winston, A. (2015). The pharmacokinetic profile of raltegravircontaining antiretroviral therapy in HIV-infected individuals over 60 years of age. HIV CLINICAL TRIALS, 16(1), 39-42. doi:10.1179/1528433614Z.0000000006

DOI
10.1179/1528433614Z.0000000006
Journal article

The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.

Vera, J. H., Jackson, A., Dickinson, L., Else, L., Barber, T., Mora-Peris, B., . . . Winston, A. (2015). The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.. HIV clinical trials, 16(1), 39-42.

Journal article

Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults

Lamorde, M., Walimbwa, S., Byakika-Kibwika, P., Katwere, M., Mukisa, L., Sempa, J. B., . . . Merry, C. (2015). Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults. J Antimicrob Chemother, 70(5), 1482-1486.

Journal article

Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy.

Waters, L., Jackson, A., Else, L., Rockwood, N., Newell, S., Back, D., . . . Boffito, M. (2015). Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy.. Antiviral therapy, 20(2), 157-163. doi:10.3851/imp2817

DOI
10.3851/imp2817
Journal article

2014

Darunavir pharmacokinetics throughout pregnancy and postpartum

Lambert, J., Jackson, V., Else, L., Lawless, M., McDonald, G., Le Blanc, D., . . . Khoo, S. (2014). Darunavir pharmacokinetics throughout pregnancy and postpartum. J Int AIDS Soc, 17(4 Supp), 19485.

Journal article

Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant

Scarsi, K., Lamorde, M., Darin, K., Dilly Penchala, S., Else, L., Nakalema, S., . . . Back, D. (2014). Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant. J Int AIDS Soc, 17(4 Supp), 19484.

Journal article

Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy

Else, L., Jackson, V., Brennan, M., Back, D. J., Khoo, S. H., Coulter-Smith, S., & Lambert, J. S. (2014). Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy. HIV Medicine, 15(10), 604-610. doi:10.1111/hiv.12164

DOI
10.1111/hiv.12164
Journal article

No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals

Singh, G. J., Jackson, A., D'Avolio, A., Else, L., De Nicolo, A., Bonora, S., . . . Boffito, M. (2014). No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals. AIDS, 28(13), 1993-1995. doi:10.1097/QAD.0000000000000356

DOI
10.1097/QAD.0000000000000356
Journal article

Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers.

Jackson, A., D'Avolio, A., Moyle, G., Bonora, S., Di Perri, G., Else, L., . . . Boffito, M. (2014). Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers.. The Journal of antimicrobial chemotherapy, 69(7), 1911-1915. doi:10.1093/jac/dku060

DOI
10.1093/jac/dku060
Journal article

A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis

Jackson, A. G. A., Else, L. J., Mesquita, P. M. M., Egan, D., Back, D. J., Karolia, Z., . . . Boffito, M. (2014). A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis. CLINICAL PHARMACOLOGY & THERAPEUTICS, 96(3), 314-323. doi:10.1038/clpt.2014.118

DOI
10.1038/clpt.2014.118
Journal article

DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI.

Di Yacovo, S., Molto, J., Ferrer, E., Curran, A., Else, L., Clotet, B., . . . Podzamczer, D. (2014). DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI.. Journal of the International AIDS Society, 17(4 Supp), 19821.

Journal article

Darunavir pharmacokinetics throughout pregnancy and postpartum

Lambert, J., Jackson, V., Else, L., Lawless, M., McDonald, G., Le Blanc, D., . . . Khoo, S. (2014). Darunavir pharmacokinetics throughout pregnancy and postpartum. Poster session presented at the meeting of Unknown Conference. Retrieved from https://www.webofscience.com/

DOI
10.7448/IAS.17.4.19485
Poster

2013

The importance of drug-drug interactions in the DAA era.

Back, D., & Else, L. (2013). The importance of drug-drug interactions in the DAA era.. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 45 Suppl 5, S343-S348. doi:10.1016/j.dld.2013.07.008

DOI
10.1016/j.dld.2013.07.008
Journal article

Validation of an electrospray ionisation LC-MS/MS method for quantitative analysis of telaprevir and its R-diastereomer

Penchala, S. D., Tjia, J., El Sherif, O., Back, D. J., Khoo, S. H., & Else, L. J. (2013). Validation of an electrospray ionisation LC-MS/MS method for quantitative analysis of telaprevir and its R-diastereomer. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 932, 100-110. doi:10.1016/j.jchromb.2013.06.013

DOI
10.1016/j.jchromb.2013.06.013
Journal article

Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.

Mora-Peris, B., Croucher, A., Else, L. J., Vera, J. H., Khoo, S., Scullard, G., . . . Winston, A. (2013). Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.. The Journal of antimicrobial chemotherapy, 68(6), 1348-1353. doi:10.1093/jac/dkt006

DOI
10.1093/jac/dkt006
Journal article

Pharmacokinetic interaction of maraviroc with tacrolimus in a patient coinfected with HIV and hepatitis B virus following hepatic transplant due to hepatocellular carcinoma.

Dufty, N. E., Gilleran, G., Hawkins, D., Else, L. J., & Taylor, S. (2013). Pharmacokinetic interaction of maraviroc with tacrolimus in a patient coinfected with HIV and hepatitis B virus following hepatic transplant due to hepatocellular carcinoma.. The Journal of antimicrobial chemotherapy, 68(4), 972-974. doi:10.1093/jac/dks486

DOI
10.1093/jac/dks486
Journal article

2012

Development and validation of a LC‐MS/MS assay to quantify intracellular tenofovir‐diphosphate (TFV‐DP) and emtricitabine‐triphosphate (FTC‐TP)

Watson, V., Else, L., Tjia, J., Khoo, S., & Back, D. (2012). Development and validation of a LC‐MS/MS assay to quantify intracellular tenofovir‐diphosphate (TFV‐DP) and emtricitabine‐triphosphate (FTC‐TP). Journal of the International AIDS Society, 15(S4), 1. doi:10.7448/ias.15.6.18336

DOI
10.7448/ias.15.6.18336
Journal article

Development and validation of a LC-MS/MS assay to quantify 10 anti-retroviral (ARV) drugs in cerebral spinal fluid (CSF)

Watson, V., Tjia, J., Szwandt, S., Else, L., Khoo, S., & Back, D. (2012). Development and validation of a LC-MS/MS assay to quantify 10 anti-retroviral (ARV) drugs in cerebral spinal fluid (CSF). Poster session presented at the meeting of 13th International Workshop on Clinical Pharmacology of HIV Therapy. Barcelona, Spain.

Poster

Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study

Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrobial Agents and Chemotherapy, 56(3), 1427-1433.

Journal article

Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations

Else, L. J., Douglas, M., Dickinson, L., Back, D. J., Khoo, S. H., & Taylor, G. P. (2012). Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(2), 816-824. doi:10.1128/AAC.05186-11

DOI
10.1128/AAC.05186-11
Journal article

Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.

Else, L., Douglas, M., Dickinson, L., Back, D. J., Khoo, S. H., & Taylor, G. P. (2012). Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.. Antimicrobial agents and chemotherapy, 56(2), 816-824.

Journal article

Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.

Else, L., Douglas, M., Dickinson, L., Back, D., Khoo, S., & Taylor, G. P. (2012). Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.. Antimicrobial agents and chemotherapy, 56(2), 816-824.

Journal article

Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study

Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrob Agents Chemother, 56(3), 1427-1433.

Journal article

Pharmacokinetics of plasma lamivudine (3TC) and its active intracellular anabolite 3TC-triphosphate (3TC-TP) over a 24 hour dosing interval following administration of 3TC 300 mg and 150 mg once daily (od) to HIV-negative healthy volunteers. The ENCORE 2 Study.

Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of plasma lamivudine (3TC) and its active intracellular anabolite 3TC-triphosphate (3TC-TP) over a 24 hour dosing interval following administration of 3TC 300 mg and 150 mg once daily (od) to HIV-negative healthy volunteers. The ENCORE 2 Study.. Antimicrob Agents Chemother.

Journal article

co-author

Jackson, A., Else, L., Tjia, J., Seymour, N., Stafford, M., Back, D., . . . Boffito, M. (2012). co-author. In 19th Conference on Retroviruses and Opportunistic Infections (pp. Paper #35). Seattle: CROI.

Conference Paper

2011

Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid)

Else, L. J., Taylor, S., Back, D. J., & Khoo, S. H. (2011). Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). ANTIVIRAL THERAPY, 16(8), 1139-1147. doi:10.3851/IMP1918

DOI
10.3851/IMP1918
Journal article

Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Male and Female Genital Tract

Else, L. J., Taylor, S., Back, D. J., & Khoo, S. H. (2011). Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Male and Female Genital Tract. Antiviral Therapy, 16(8), 1149-1167. doi:10.3851/imp1919

DOI
10.3851/imp1919
Journal article

Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies

Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(6), 2775-2782. doi:10.1128/AAC.00887-10

DOI
10.1128/AAC.00887-10
Journal article

Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies.

Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies.. Antimicrobial agents and chemotherapy, 55(6), 2775-2782.

Journal article

Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy

Else, L. J., Lyons, F., O'Shea, S., Costello, S., Mullen, J., Lechelt, M., . . . de Ruiter, A. (2011). Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy. AIDS, 25(5), 722-725. doi:10.1097/QAD.0b013e3283445700

DOI
10.1097/QAD.0b013e3283445700
Journal article

Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy.

Else, L., Lyons, F., O'shea, S., Costello, S., Mullen, J., Lechelt, M., . . . de Ruiter, A. (2011). Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy.. AIDS, 25(5), 722-725.

Journal article

Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy

Lambert, J. S., Else, L. J., Jackson, V., Breiden, J., Gibbons, S., Dickinson, L., . . . Khoo, S. H. (2011). Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Medicine, 12(3), 166-173. doi:10.1111/j.1468-1293.2010.00865.x

DOI
10.1111/j.1468-1293.2010.00865.x
Journal article

Pharmacokinetics of plasma lamivudine (3TC) and its active intracellular anabolite 3TC-triphosphate (3TC-TP) over a 24 hour dosing interval following administration of 3TC 300 mg and 150 mg once daily (od) to HIV-negative healthy volunteers. The ENCORE 2 Study.

Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2011). Pharmacokinetics of plasma lamivudine (3TC) and its active intracellular anabolite 3TC-triphosphate (3TC-TP) over a 24 hour dosing interval following administration of 3TC 300 mg and 150 mg once daily (od) to HIV-negative healthy volunteers. The ENCORE 2 Study.. In 12th International Workshop on Clinical Pharmacology of HIV Therapy (pp. oral communication). Miami: Virology Education.

Conference Paper

Saliva Nevirapine (NVP) Concentrations as an Alternative Biofluid for NVP Pharmacokinetics (PK) in HIV-infected Children.

Else, L., Sabo, J., Yong, C., Macgregor, T. R., Eaton, S., Rinck, G., . . . Back, D. J. (2011). Saliva Nevirapine (NVP) Concentrations as an Alternative Biofluid for NVP Pharmacokinetics (PK) in HIV-infected Children.. In 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (pp. A1-A1164). Chicago: American Society for Microbiology.

Conference Paper

Sequential population modelling of lopinavir and ritonavir in healthy volunteers and assessment of different doing strategies

Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential population modelling of lopinavir and ritonavir in healthy volunteers and assessment of different doing strategies. Antimicrob Agents Chemother, 55(6), 2775-2782.

Journal article

2010

Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100, 200/150, and 200/50 mg twice daily in HIV‐negative volunteers

Jackson, A. G. A., Hill, A., Else, L. J., Back, D. J., Morley, R., Puls, R., . . . Boffito, M. (2010). Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100, 200/150, and 200/50 mg twice daily in HIV‐negative volunteers. Journal of the International AIDS Society, 13(S4). doi:10.1186/1758-2652-13-s4-p180

DOI
10.1186/1758-2652-13-s4-p180
Journal article

Darunavir concentrations exceed the protein-corrected EC<sub>50</sub> for wild-type HIV in the semen of HIV-1-infected men

Taylor, S., Jayasuriya, A. N., Berry, A., Gilleran, G., Dufty, N. E., Else, L., . . . Smit, E. J. (2010). Darunavir concentrations exceed the protein-corrected EC<sub>50</sub> for wild-type HIV in the semen of HIV-1-infected men. AIDS, 24(16), 2574-2577. doi:10.1097/QAD.0b013e32833ead18

DOI
10.1097/QAD.0b013e32833ead18
Journal article

Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds

Else, L., Watson, V., Tjia, J., Hughes, A., Siccardi, M., Khoo, S., & Back, D. (2010). Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 878(19), 1455-1465. doi:10.1016/j.jchromb.2010.03.036

DOI
10.1016/j.jchromb.2010.03.036
Journal article

Evaluating the affect of gender on darunavir and ritonavir (DRV/r) exposure in HIV infected subjects (a post-hoc analysis of the GRACE PK sub-study).

Else, L., Liptrott, N., Moss, D., Dutton, J., Fraser, W., Kakuda, T., . . . Back, D. (2010). Evaluating the affect of gender on darunavir and ritonavir (DRV/r) exposure in HIV infected subjects (a post-hoc analysis of the GRACE PK sub-study).. In 11th International Workshop on Clinical Pharmacology of HIV Therapy. (pp. P19). Sorrento: Virology Education.

Conference Paper

Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.

Jackson, A., Hill, A., Puls, R., Else, L., Amin, J., Back, D., . . . Boffito, M. (2010). Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.. J Antimicrob Chemother..

Journal article

Raltegravir (RAL) in combination with etravirine (ETV) - is there a case for therapeutic drug monitoring (TDM) in clinical practice?

Leake Date, H., Else, L., Dosekun, O., Back, D., Nathan, B., Kulasegaram, R., & Aboud, M. (2010). Raltegravir (RAL) in combination with etravirine (ETV) - is there a case for therapeutic drug monitoring (TDM) in clinical practice?. In Second Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH). (pp. P6). Manchester: BHIVA.

Conference Paper

Therapeutic drug monitoring (TDM) of lopinavir/ritonavir (LPV/r) in pregnancy.

Else, L., Lambert, J. S., Jackson, V., Breiden, J., Gibbons, S., Dickinson, L., . . . Khoo, S. (2010). Therapeutic drug monitoring (TDM) of lopinavir/ritonavir (LPV/r) in pregnancy.. In Second Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH). (pp. P12). Manchester: HIV Med.

Conference Paper

Therapeutic drug monitoring of lopinavir in pregnancy.

Lambert, J. S., Else, L., Jackson, V., Breiden, J., Gibbons, S., Dickinson, L., . . . Khoo, S. H. (2010). Therapeutic drug monitoring of lopinavir in pregnancy.. HIV Med. doi:10.1111/j.1468-1293.2010.00865.x

DOI
10.1111/j.1468-1293.2010.00865.x
Journal article

Total and unbound lopinavir/ritonavir (LPV/r) concentrations in the genital tract (fGT) of HIV-1 infected women during pregnancy.

Lyons, F., Else, L., O'Shea, S., Costello, S., Mullen, J., Lechelt, M., . . . de Ruiter, A. (2010). Total and unbound lopinavir/ritonavir (LPV/r) concentrations in the genital tract (fGT) of HIV-1 infected women during pregnancy.. In Second Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH) (pp. P9). Manchester: BHIVA.

Conference Paper

Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.

Else, L., Watson, V., Tjia, J., Hughes, A., Siccardi, M., Khoo, S., & Back, D. J. (2010). Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.. Chromatogr B Analyt Technol Biomed Life Sci., 878(19), 1455-1465.

Journal article

2009

Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.

Pollock, L., Else, L., Poerksen, G., Molyneux, E., Moons, P., Walker, S., . . . Khoo, S. (2009). Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.. The Journal of antimicrobial chemotherapy, 64(6), 1251-1259. doi:10.1093/jac/dkp358

DOI
10.1093/jac/dkp358
Journal article

Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients.

Yilmaz, A., Watson, V., Else, L., & Gisslèn, M. (2009). Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients.. AIDS (London, England), 23(18), 2537-2540. doi:10.1097/qad.0b013e328333ae0e

DOI
10.1097/qad.0b013e328333ae0e
Journal article

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.

Dickinson, L., Boffito, M., Back, D., Waters, L., Else, L., Davies, G., . . . Aarons, L. (2009). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.. The Journal of antimicrobial chemotherapy, 63(6), 1233-1243.

Journal article

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers

Dickinson, L., Boffito, M., Back, D., Waters, L., Else, L., Davies, G., . . . Aarons, L. (2009). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 63(6), 1233-1243. doi:10.1093/jac/dkp102

DOI
10.1093/jac/dkp102
Journal article

Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients.

Yilmaz, A., Watson, V., Else, L., & Gissien, M. (2009). Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients.. AIDS, 23(18), 2537-2540.

Journal article

Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.

Pollock, L., Else, L., Poerksen, G., Molyneux, E., Moons, P., Walker, S., . . . Khoo, S. (2009). Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.. J Antimicrob Chemother., 64(6), 1251-1259.

Journal article

2008

Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.

Moltó, J., Santos, J. R., Pérez-Alvarez, N., Cedeño, S., Miranda, C., Khoo, S., . . . Clotet, B. (2008). Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.. Antimicrobial agents and chemotherapy, 52(11), 3928-3932.

Journal article

Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.

Moltó, J., Santos, J. R., Pérez-Alvarez, N., Cedeño, S., Miranda, C., Khoo, S., . . . Clotet, B. (2008). Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.. Antimicrobial agents and chemotherapy, 52(11), 3928-3932. doi:10.1128/aac.00520-08

DOI
10.1128/aac.00520-08
Journal article

Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation

Back, D., Else, L., Khoo, S., Boffito, M., Taylor, J., Sousa, M., . . . Moyle, G. (2008). Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. ANTIVIRAL THERAPY, 13(7), 901-907.

Journal article

Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.

Boffito, M., Else, L., Back, D., Taylor, J., Khoo, S., Sousa, M., . . . Moyle, G. (2008). Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.. Antiviral therapy, 13(7), 901-907.

Journal article

Therapeutic Drug Monitoring of new formulation Kaletra in pregnancy

Else, L., Jackson, V., Khoo, S., Gibbons, S., Brennan, M., O Connor, E., . . . Lambert, J. S. (2008). Therapeutic Drug Monitoring of new formulation Kaletra in pregnancy. In The 9th International Congress on Drug Therapy in HIV Infection Vol. 11 (pp. P119). Glasgow: Journal of the International AIDS Society.

Conference Paper

Total and unbound nevirapine (NVP) pharmacokinetics (PK) in HIV-infected children treated with divided fixed-dose combination (FDC) tablets in Malawi.

Else, L., Pollock, L., Poerkson, G., Back, D. J., Khoo, S. H., Fraser, W., . . . Molyneux, E. (2008). Total and unbound nevirapine (NVP) pharmacokinetics (PK) in HIV-infected children treated with divided fixed-dose combination (FDC) tablets in Malawi.. In 9th International Workshop on Clinical Pharmacology of HIV Therapy (pp. O7). New Orleans: Virology Education.

Conference Paper

Validation of an ultra-sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for simultaneous determination of 11 anti-retroviral compounds.

Else, L., Watson, V., Tjia, J., Siccardi, M., Khoo, S. H., & Back, D. J. (2008). Validation of an ultra-sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for simultaneous determination of 11 anti-retroviral compounds.. In British Pharmacological Society Winter Meeting (pp. n/a). Brighton: British Pharmacological Society, 16 Angel Gate, City Road, London, UK.

Conference Paper

2007

Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.

Waters, L. J., Moyle, G., Bonora, S., D'Avolio, A., Else, L., Mandalia, S., . . . Boffito, M. (2007). Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.. Antiviral therapy, 12(5), 825-830.

Journal article